Literature DB >> 27708280

Antiplatelet therapy: What have we learned from the ANTARCTIC trial?

Paul A Gurbel1, Udaya S Tantry1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27708280     DOI： 10.1038/nrcardio.2016.167

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.

Authors:  Guillaume Cayla; Thomas Cuisset; Johanne Silvain; Florence Leclercq; Stephane Manzo-Silberman; Christophe Saint-Etienne; Nicolas Delarche; Anne Bellemain-Appaix; Grégoire Range; Rami El Mahmoud; Didier Carrié; Loic Belle; Geraud Souteyrand; Pierre Aubry; Pierre Sabouret; Xavier Halna du Fretay; Farzin Beygui; Jean-Louis Bonnet; Benoit Lattuca; Christophe Pouillot; Olivier Varenne; Ziad Boueri; Eric Van Belle; Patrick Henry; Pascal Motreff; Simon Elhadad; Joe-Elie Salem; Jérémie Abtan; Hélène Rousseau; Jean-Philippe Collet; Eric Vicaut; Gilles Montalescot
Journal:  Lancet       Date:  2016-08-28       Impact factor: 79.321

2.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry
Journal:  J Am Coll Cardiol       Date:  2005-10-21       Impact factor: 24.094

3.  Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.

Authors:  David Erlinge; Paul A Gurbel; Stefan James; Tomas L Lindahl; Peter Svensson; Jurrien M Ten Berg; David P Foley; Henrik Wagner; Patricia B Brown; Junxiang Luo; Chunmei Zhou; Brian A Moser; Joseph A Jakubowski; David S Small; Kenneth J Winters; Dominick J Angiolillo
Journal:  J Am Coll Cardiol       Date:  2013-06-07       Impact factor: 24.094

4.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

5.  Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.

Authors:  Gianluca Campo; Luca Fileti; Nicoletta de Cesare; Emanuele Meliga; Alessandro Furgieri; Filippo Russo; Salvatore Colangelo; Salvatore Brugaletta; Roberto Ferrari; Marco Valgimigli
Journal:  J Am Coll Cardiol       Date:  2010-10-26       Impact factor: 24.094

6.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

Authors:  Laurent Bonello; Laurence Camoin-Jau; Stéphane Arques; Christian Boyer; Dimitri Panagides; Olivier Wittenberg; Marie-Claude Simeoni; Paul Barragan; Françoise Dignat-George; Franck Paganelli
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

Review 7.  Platelet-Mediated Thrombosis: From Bench to Bedside.

Authors:  Paul A Gurbel; Young-Hoon Jeong; Eliano P Navarese; Udaya S Tantry
Journal:  Circ Res       Date:  2016-04-29       Impact factor: 17.367

8.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

Authors:  Jean-Philippe Collet; Thomas Cuisset; Grégoire Rangé; Guillaume Cayla; Simon Elhadad; Christophe Pouillot; Patrick Henry; Pascal Motreff; Didier Carrié; Ziad Boueri; Loic Belle; Eric Van Belle; Hélène Rousseau; Pierre Aubry; Jacques Monségu; Pierre Sabouret; Stephen A O'Connor; Jérémie Abtan; Mathieu Kerneis; Christophe Saint-Etienne; Olivier Barthélémy; Farzin Beygui; Johanne Silvain; Eric Vicaut; Gilles Montalescot
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245

9.  Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.

Authors:  Paul A Gurbel; David Erlinge; E Magnus Ohman; Benjamin Neely; Megan Neely; Shaun G Goodman; Kurt Huber; Mark Y Chan; Jan H Cornel; Eileen Brown; Chunmei Zhou; Joseph A Jakubowski; Harvey D White; Keith A A Fox; Dorairaj Prabhakaran; Paul W Armstrong; Udaya S Tantry; Matthew T Roe
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272

Review 10.  Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.

Authors:  Jean-Luc Reny; Pierre Fontana; Willibald Hochholzer; Franz Josef Neumann; Jurriën Ten Berg; Paul W Janssen; Tobias Geisler; Meinrad Gawaz; Rossella Marcucci; Anna-Maria Gori; Thomas Cuisset; Marie-Christine Alessi; Philippe Berdagué; Paul A Gurbel; Gerald Yong; Dominick J Angiolillo; Dániel Aradi; Roy Beigel; Gianluca Campo; Christophe Combescure
Journal:  Thromb Haemost       Date:  2015-11-26       Impact factor: 5.249
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.